Grants Search Results

Need help? Call us at (888) 899-2253

Interested in applying for a St. Baldrick's Foundation grant? Learn more about the grant application process.

Showing 1681-1700 of 2411 results

Kris Ann Schultz M.D. 

Researcher Photo

Funded: 09-01-2011 through 11-30-2016
Funding Type: St. Baldrick's Scholar
Institution Location: Minneapolis, MN
Institution: Children's Hospitals and Clinics of Minnesota affiliated with Children's - St. Paul

Based on progress to date, Dr. Schultz was awarded a new grant in 2014 to fund an additional two years of this Scholar award. Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood, have recently been found to be associated with a lung cancer of early childhood called pleuropulmonary blastoma (PPB). The cause of these ovarian tumors is unknown. DICER1 mutations are seen in the majority of children with PPB and also in some patients with ovarian tumors. Like PPB, ovarian stromal tumors are highly curable when found in early stage; however, later forms of the disease are aggressive and often fatal. This project establishs the International Ovarian Stromal Tumor Registry to collect clinical and biologic data. Understanding these rare tumors will lead to increasing survival and reducing late effects. The Registry provides information to improve the direct care of children with these conditions and facilitate future research.  

Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium

Funded: 09-01-2011 through 08-31-2015
Funding Type: Consortium Research Grant
Institution Location: Dallas, TX
Institution: University of Texas Southwestern Medical Center at Dallas

Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), the most common class of soft tissue sarcoma, afflicts children and young adults. Unlike children with rhabdomyosarcoma, chemotherapy has failed to improve survival for NRSTS. Of the nearly 50% with intermediate or high-risk NRSTS, only 50% and 15%, respectively, are expected to survive. This consortium is taking advantage of new technology platforms to identify the so-called "actionable mutations" in NRSTS specimens. From this foundation, researchers are able to use molecular genetic data to guide treatment decisions for individual patients with NRSTS. Funds originally administered by the University of Chicago and transferred to the University of Texas Southwestern Medical Center at Dallas.

Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium Member

Funded: 09-01-2011 through 08-31-2015
Funding Type: Consortium Research Grant
Institution Location: Omaha, NE
Institution: University of Nebraska affiliated with Children's Hospital & Medical Center, Nebraska

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium Member

Funded: 09-01-2011 through 08-31-2015
Funding Type: Consortium Research Grant
Institution Location: Seattle, WA
Institution: Seattle Children's Hospital affiliated with Fred Hutchinson Cancer Research Center, University of Washington

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium Member

Funded: 09-01-2011 through 08-31-2015
Funding Type: Consortium Research Grant
Institution Location: Columbus, OH
Institution: The Research Institute at Nationwide affiliated with Nationwide Children's Hospital

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium Member

Funded: 09-01-2011 through 08-31-2015
Funding Type: Consortium Research Grant
Institution Location: Memphis, TN
Institution: St. Jude Children's Research Hospital

This institution is a member of a research consortium which is being funded by St. Baldrick's: Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma Consortium. For a description of this project, see the consortium grant made to the lead institution: the University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

Consortium for Pediatric Intervention Research

Funded: 07-01-2011 through 06-30-2014
Funding Type: Consortium Research Grant
Institution Location: Duarte, CA
Institution: Beckman Research Institute of the City of Hope

There are currently over 350,000 childhood cancer survivors in the U.S., but treatments often result in persistent late-occurring health problems. One of the most devastating is congestive heart failure (CHF) resulting from treatment with a class of chemotherapy drugs called anthracyclines. It is estimated that 1 in 10 children treated with high-dose anthracyclines will develop CHF, with 1 in 2 dying within five years of diagnosis of CHF. Studies indicate that a low-dose blood pressure medication called carvedilol may help prevent the onset of CHF. This Consortium for Pediatric Intervention Research conducts a clinical trial with collaboration between five COG-member institutions. The project has the potential to not only improve overall cardiac function, but prevent the likelihood of developing CHF in survivors at highest risk. Funds administered by Beckman Research Institute of the City of Hope. Year two of this grant was generously funded by the Rally Foundation.

Vandana Batra M.D. 

Researcher Photo

Funded: 07-01-2011 through 06-30-2014
Funding Type: St. Baldrick's Fellow
Institution Location: Philadelphia, PA
Institution: The Children's Hospital of Philadelphia affiliated with University of Pennsylvania

Based on progress to date, Dr. Batra was awarded a new grant in 2013 to fund an optional third year of this fellowship. Neuroblastoma (NB) is a cancer that affects children and infants and cure rates are 40-50% range for high-risk NB. Fortunately, this disease is exquisitely sensitive to radiation. MIBG, a compound similar to adrenaline, has been shown to be effective for treating bulk disease, but is not able to destroy cancer cells that are widely distributed. This project focuses on an innovative method to circumvent this problem by designing an "alpha-emitting" radioisotope called 211At MABG. Alpha particles, which have been much more difficult to design as medicines, have the major advantage of much higher radiation energy and a much shorter range of action, so that they will kill the cells that take it up. This will be a major milestone in neuroblastoma therapy and provide a novel targeted radiotherapeutic approach to pediatric cancer.

The Markit St. Baldrick's Consortium Research Grant:  Childhood and Adolescent Lymphoma Cell Therapy Consortium (CALCTC)

Funded: 07-01-2011 through 06-30-2018
Funding Type: Consortium Research Grant
Institution Location: Valhalla, NY
Institution: New York Medical College affiliated with Maria Fareri Children's Hospital at Westchester Medical Center

Lymphoma is the most common cancer in adolescents and young adults (AYA) (15-30 years) and the third most common cancer in children (C) under the age of 15 years (CAYA). This childhood, adolescent and young adult lymphoma cell therapy consortium brings together 8 multidisciplinary academic centers to facilitate targeted cell based translational research in poor-risk and rare lymphomas. This project will likely increase long-term complete remissions, decrease late effects and secondary cancers, reduce health care expenditures and provide a strategy for similar targeted cell based therapy strategies for CAYA patients with poor-risk lymphomas and other similar malignancies. Funds administered by New York Medical College.  

This grant is named for Markit, Ltd. whose 24-hour head-shaving events worldwide have raised over $2.2 million since 2007 to fund life-saving research through the St. Baldrick’s Foundation.

Clinton Carroll M.D. 

Researcher Photo

Funded: 07-01-2011 through 06-30-2013
Funding Type: St. Baldrick's Fellow
Institution Location: Nashville, TN
Institution: Vanderbilt University Medical Center affiliated with Monroe Carell Jr. Children's Hospital at Vanderbilt

To treat cancer effectively we must first understand why cancer develops. The body is constantly producing cells which make up our tissues. Often, when a cell develops chromosomal damage, the cell is fixed by multiple proteins referred to as the DNA Damage Response (DDR), or the cell is eliminated through a process called apoptosis. Unfortunately, some damaged cells escape these processes because the DDR does not work properly, and they go on to divide and form cancer. This project focuses on understanding one aspect of the DDR, a protein called SMARCAL1, to gain insight into why normal cells become genetically unstable and cancerous, and to uncover proteins and pathways that might serve as novel targets for cancer drugs, to help eventually eradicate of childhood cancer. 

Sharon Castellino M.D., M.Sc.

Researcher Photo

Funded: 07-01-2011 through 06-30-2012
Funding Type: Supportive Care Research Grant
Institution Location: Winston Salem, NC
Institution: Wake Forest University Health Sciences affiliated with Brenner Children's Hospital

While currently 70% of children with brain tumors survive beyond 5-years from diagnosis, radiation to the brain and spine are cornerstones of therapy. The cost of this treatment is impaired neuro-cognitive function, premature heart problems, stroke, and impaired quality of life in many. The role of injury to the heart and vascular system from radiation has not been previously studied in childhood brain tumor survivors. While killing tumor cells, radiation may lead to narrowing and stiffening of the vessels in the brain. Stiffening of the aorta is a progressive with normal aging in the lifespan. This project studies stiffness in the aorta and its relation to flow in the vessels in the brain among children who received radiation therapy, a novel attempt to link the heart and the brain following childhood cancer. 

Tiffany Chang M.D. 

Researcher Photo

Funded: 07-01-2011 through 06-30-2014
Funding Type: St. Baldrick's Fellow
Institution Location: San Francisco, CA
Institution: University of California, San Francisco affiliated with UCSF Benioff Children's Hospital

Based on progress to date, Dr. Chang was awarded a new grant in 2013 to fund an optional third year of this fellowship. Children with Neurofibromatosis Type 1 (NF1) are strongly predisposed to Juvenile Myelomonocytic Leukemia (JMML), a relentless form of cancer. Only 50% of children with JMML survive beyond 5 years, and hematopoietic stem cell transplantation currently offers the only potential for cure, although transplant-related mortality is high. Therapies targeted to specific molecular abnormalities in JMML may offer a better alternative. Ras is a protein involved in normal cellular growth as well as malignant transformation. Understanding the therapeutic effects of inhibiting Ras effector pathways will inform novel treatment strategies.

Rishikesh Chavan M.D. 

Researcher Photo

Funded: 07-01-2011 through 06-30-2012
Funding Type: St. Baldrick's Fellow
Institution Location: Houston, TX
Institution: Baylor College of Medicine affiliated with Vannie E. Cook Jr. Children's Cancer and Hematology Clinic, Texas Children's Hospital

Cancer is caused by alterations (mutations) in the genetic material of tumor cells. The identification of these mutations has allowed the development of treatments specifically targeted at the mutated genes, resulting in remarkable clinical advances for a few specific cancer types. This proposal uses state-of-the-art sequencing technologies to analyze hepatoblastoma, the most common liver cancer of children. The goal of this project is to dramatically shift current research and treatment paradigms by directing investigators to the most relevant genes causing hepatoblastoma, which are currently largely unknown.  

Samuel Cheshier M.D., Ph.D. 

Researcher Photo

Funded: 07-01-2011 through 09-30-2012
Funding Type: Research Grant
Institution Location: Palo Alto, CA
Institution: Stanford University affiliated with Lucile Packard Children’s Hospital

Diffuse Intrinsic Pontine Glioma (DIPG) and Medulloblastoma (MB) are the two most common malignant brain tumors in children, highly aggressive tumors that cause disability and death. A new concept in cancer biology is the cancer stem cell hypothesis, which states that tumors are initiated and maintained by a small fraction of cells with stem cell-like properties. This hypothesis could explain many of the mysteries of cancer biology, one of them being the recurrence of the same tumor despite aggressive radiation and chemotherapy. This study uses a computer program called MiDReg with DIPG and MB tumor samples to learn more and ultimately develop safer and better treatments.

Rachel Thienprayoon M.D. 

Researcher Photo

Funded: 07-01-2011 through 06-30-2013
Funding Type: St. Baldrick's Fellow
Institution Location: Dallas, TX
Institution: University of Texas Southwestern Medical Center at Dallas

Pediatric palliative care is a comprehensive system of care aimed at preventing or relieving symptoms and suffering caused by a life-threatening illness. At the end of life, hospice is an important provider of palliative care. The goal of this study is to identify factors that are associated with hospice use in pediatric oncology, about which little is known. Although cure rates have dramatically increased in pediatric cancer, palliative care and hospice are an integral part of caring for the patients who do not survive. A better understanding of why parents and patients choose hospice can help improve the care of pediatric oncology patients at the end of life.

Lionel Chow M.D., Ph.D. 

Researcher Photo

Funded: 07-01-2011 through 06-30-2016
Funding Type: St. Baldrick's Scholar
Institution Location: Cincinnati, OH
Institution: Cincinnati Children's Hospital Medical Center affiliated with University of Cincinnati College of Medicine

Based on progress to date, Dr. Chow was awarded a new grant in 2014 to fund an additional two years of this Scholar award. High-grade gliomas (HGGs) are aggressive brain tumors in children, extremely difficult to treat. Current therapies are ineffective and the majority of patients succumb to their disease, with HGG responsible for a significant portion of cancer-related deaths in children. To date, the majority of research on HGG has been conducted on tumors in adults, but there is evidence that HGGs in children have different characteristics, which suggests that treatments for adults may not be effective in children. This study is to better understand how HGGs arise and grow in children in order to tailor treatment to this population and identify combinations of drugs that will improve survival.

The International Neuroblastoma Risk Group (INRG) Task Force with generous support from the Just Do It...and be done with it Hero Fund

Funded: 07-01-2011 through 06-30-2016
Funding Type: Consortium Research Grant
Institution Location: Chicago, IL
Institution: The University of Chicago affiliated with Comer Children's Hospital

The International Neuroblastoma Risk Group (INRG) Task Force has collected data on over 11,500 children with neuroblastoma. These data are available to researchers from around the world, and seminal discoveries have already been made using this unique collection of patient data. However, the current application housing the INRG data has significant limitations, and this project develops tools to overcome those. The INRG has recently reported racial disparities in outcome in neuroblastoma, and studies indicate genetic factors contribute to the poor outcome seen in the black cohort. Banked DNA samples will be identified and used to learn the variables contributing to these disparities. The goal of the Interactive INRG database is to transform neuroblastoma research by enabling studies on large international cohorts of patients never before possible. Funds administered by the University of Chicago.  This grant is generously supported by the “Just Do It…and be done with it” Hero Fund created in honor of Sara Martorano and celebrates the courage of all kids with cancer through treatment and the support of their family and friends.

Ex vivo expanded hematopoietic progenitors for AML supportive care Clinical Trial Consortium

Funded: 07-01-2011 through 06-30-2017
Funding Type: Consortium Research Grant
Institution Location: Seattle, WA
Institution: Fred Hutchinson Cancer Research Center affiliated with University of Washington, Seattle Children's Hospital

The intensive chemotherapy that is required to treat pediatric acute myelogenous leukemia (AML) results in prolonged periods of extremely low white blood cell counts, which in turn is associated with a significant risk of death from infectious complications. In fact, treatment related mortality is as high as 20% in adolescents and young adults undergoing chemotherapy for AML. This study aims to test potential new therapies that can help overcome the low white blood cell count (neutropenia) that results from intensive chemotherapy, to reduce the risk of infectious complications. Funds administered by Fred Hutchinson Cancer Research Center.

Jennifer Elster M.D.

Funded: 07-01-2011 through 06-30-2013
Funding Type: St. Baldrick's Fellow
Institution Location: Pittsburgh, PA
Institution: University of Pittsburgh affiliated with Children's Hospital of Pittsburgh

A growing tumor requires a blood supply, and in some tumors, such as neuroblastoma, the number of blood vessels in a tumor correlates with metastases and mortality. The formation of new blood vessels is called angiogenesis. Anti-angiogenic drugs designed to stop these blood vessels from forming have proved disappointing, so far. The lab in which Dr. Elster is working has identified one reason for this. In this project, known pharmacologically active compounds are screened to find what may be the backbone for the next class of anti-angiogenic drugs.

Adolfo Ferrando M.D., Ph.D. 

Researcher Photo

Funded: 07-01-2011 through 06-30-2012
Funding Type: Research Grant
Institution Location: New York, NY
Institution: Columbia University Medical Center affiliated with Morgan Stanley Children’s Hospital, New York-Presbyterian

T-cell acute lymphoblastic leukemia is an aggressive cancer that requires highly intensive chemotherapy, and the prognosis of patients with relapsed and refractory T-ALL is very poor. The genetic lesions responsible for progression and relapse in this disease remain largely unknown. The goals of this project are to identify novel pathogenic genes and pathways in relapsed and refractory T-ALL, to assess their contribution to T-cell transformation and chemotherapy resistance. These results will be ultimately translated in new diagnostic tools to identify high-risk patients and in new molecular targeted drugs for the treatment of this disease.